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Abstract
Background: A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is
not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the
risk of CV events among antiretroviral-naïve patients initiating ATV-containing versus ATV-free ARV regimens.
Methods: Patients with HIV who newly initiated antiretroviral therapy were selected from MarketScan Commercial
and Multi-State Medicaid databases. The first claim for an antiretroviral medication between 1/1/2007 and 12/31/2013
was known as the index date. Patients were categorized as initiating an ATV-containing or an ATV-free regimen.
Patients who did not have 6 months of continuous enrollment prior to the index date or who had evidence of a CV
event during this time period were excluded. Myocardial infarction, stroke, percutaneous coronary intervention, and
coronary artery bypass graft were identified through diagnosis and procedure codes. Patients were followed from
index date until a CV event, continuous gap of >30 days without initiated ARV, a claim for ATV in the ATV-free
cohort, disenrollment, or study end, whichever occurred first. Unadjusted incidence rates (IR) were calculated and
propensity-score-weighted Cox proportional hazards models were fit to compare hazards of CV events between
the two cohorts.
Results: A total of 22,211 patients (2437 ATV-containing and 19,774 ATV-free) were identified in the Commercial
Database and 7136 patients were identified (1505 ATV-containing and 5631 ATV-free) in the Medicaid Database.
CV events were uncommon (Commercial IR per 1000 person-years for a CV event: ATV-containing = 3.01, ATV-free = 3.26;
Medicaid IR: ATV-containing = 10.9, ATV-free = 9.9). In propensity-score-weighted models combining the two populations,
there was no significant difference in the hazards of a CV event for patients initiating an ATV-containing regimen
compared with those initiating an ATV-free regimen (hazard ratio = 1.16, 95 % confidence interval 0.67–1.99).
Conclusions: In this real-world analysis, there was no significant increase in the risk of CV events associated with
exposure to ATV-containing regimens.
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Background
Cardiovascular (CV) disease is of clinical importance
among individuals with HIV. Several analyses have re-
ported that risk of CV disease is higher among people
with HIV compared to uninfected individuals, even
after adjusting for traditional risk factors [1–4]. Use of
certain antiretroviral (ARV) medications used to treat
HIV infection have been implicated in this increased
risk [1, 5]. Analyses of older data have found that use of
protease inhibitors (PIs), one class of antiretroviral
medications, is associated with increased risk for CV
events [1, 5]. One large prospective study, the Data Collec-
tion on Adverse Events of Anti-HIV Drugs (D:A:D), re-
ported that use of PIs was associated with myocardial
infarction (MI), due in part to dyslipidemia, based on data
collected through 2005 [6]. A systematic review and meta-
analysis using analyses published through 2011 found that
cumulative exposure to PIs, particularly indinavir and
lopinavir, was also associated with increased risk of MI [5].
However, there is not as much data available with more
recently approved PIs, and the available studies have not
found the same association with CV disease. An analysis
evaluating atazanavir (ATV) use and risk for MI or stroke
in the D:A:D cohort reported no significant association
with either outcome [7]. Additionally, a recent random-
ized clinical trial reported that treatment-naïve patients
who initiated ritonavir-boosted ATV (ATV/r) had sig-
nificantly slower progression of atherosclerosis over a
3-year period compared to patients treated with ritonavir-
boosted darunavir (DRV/r) [8]. These patients also had
slower progression compared with patients treated with
raltegravir, though the difference was only statistically sig-
nificant at the carotid bifurcation and in the on-treatment
analyses [8]. In combination, these analyses suggest that
not all medications within the PI class have the same CV
risk profile.
In order to confirm these findings, the primary objective
of this claims-based analysis was to compare incidence rates
and hazards of CV events between antiretroviral-naïve HIV
+ patients initiating ATV-containing versus ATV-free ARV
regimens. The secondary objectives were to compare these
outcomes between HIV+ patients initiating ATV-containing
regimens versus (a) PI-free regimens, (b) other PI-con-




The Truven Health MarketScan® Commercial Claims
and Encounters (Commercial) and Multi-State Medicaid
(Medicaid) insurance claims databases were used to con-
duct this analysis. The databases contain inpatient and
outpatient medical claims, outpatient prescription drug
claims, and enrollment information of enrollees from a
variety of fee-for-service and managed care health plans
from a convenience sample of over 300 large self-insured
employers and over 25 health plans, and similar claims
from Medicaid insurance from 15 geographically dis-
persed states in the US. Patients are included in the
database if their health insurer is one of the data con-
tributors to MarketScan. They remain in the database
until they become unenrolled. For example, if a patient
has insurance through his/her employer and the em-
ployer is a contributor to MarketScan, that patient
would be included in the MarketScan enrollment files
until he/she switched employers. If the patient was with
that employer for 3 years, all healthcare claims generated
by the patient in those 3 years (i.e., office visits, prescrip-
tions, etc.) would appear in the MarketScan database.
There are approximately 138 million enrollees in the
Commercial database and approximately 29 million
enrollees in the Medicaid database. All records contained
within the databases are statistically de-identified and fully
compliant with the conditions designated by the Health
Insurance Portability and Accountability Act (HIPAA)
Privacy Regulations. Institutional Review Board approval
was not sought, as the data did not contain any individu-
ally identifiable patient information.
Patient selection
Patients with at least one prescription claim with a Na-
tional Drug Code for ATV, another PI, a non-nucleoside
reverse transcriptase inhibitor (NNRTI), an integrase in-
hibitor, a fusion inhibitor, or a CCR5 antagonist between
January 1, 2007 and December 31, 2013 were selected
from the Commercial and Medicaid databases. The date
of first claim was known as the index date and the medi-
cation filled on that date was defined as the index drug.
The following inclusion criteria were then applied to the
initial group of patients: age 18–64 on the index date,
continuous enrollment for at least six months prior to
the index date, no evidence of a CV event of interest
(MI, stroke, percutaneous coronary intervention [PCI], or
coronary artery bypass graft [CABG]) in the six months
prior to the index date, at least one medical claim with a
diagnosis of HIV infection (International Classification
of Diseases, Ninth Edition, Clinical Modification [ICD-
9-CM] 042, V08, 795.71, 079.53) prior to index date
using all available data starting in 2004, no claims for
ARV medications prior to the index date using all avail-
able prior data starting in 2004 to attempt to ensure pa-
tients were treatment-naïve, and no dual eligibility for
Medicare. The final patient samples were categorized
into two cohorts based on ARV claims on the index
date for the primary analysis: ATV-containing regimen
cohort or ATV-free regimen cohort. To address the sec-
ondary objectives, patients initiating ATV-free regimens
were further categorized as initiating PI-free regimens,
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other PI-containing regimens, and DRV-containing regi-
mens. Full patient attrition is shown in Table 1.
Study time period
The study period consisted of a baseline period, index
date, and a variable-length follow-up period. The base-
line period, during which patient characteristics were
measured, was the six months prior to the index date.
As described above, the index date was the date of anti-
retroviral therapy (ART) initiation. Patients were followed
from the index date to the occurrence of a CV event, a
gap of >30 consecutive days without index drug, a claim
for ATV for patients in the ATV-free cohort, disenroll-
ment, or end of the available data. Follow-up was calcu-
lated separately for each individual CV event. Patients
were not required to be on ARV medications for any pre-
specified length of time during the follow-up period. In
intent-to-treat (ITT) sensitivity analyses, patients were
followed from index date until a CV event, end of con-
tinuous enrollment, or end of the study data, regardless of
changes to ARV medications.
CV outcomes
Medical claims during the follow-up period were evalu-
ated for diagnosis or procedure codes indicative of the
following CV events: MI, stroke, PCI, or CABG. Add-
itionally, a composite CV event was captured which in-
cluded any of the aforementioned events. The presence
of an MI was determined by an inpatient medical claim
with a diagnosis code for MI (ICD-9-CM 410.xx) re-
corded in the primary diagnosis position [9]. Similarly,
stroke was defined as an inpatient medical claim with a
diagnosis code for stroke (ICD-9-CM 430.xx, 431.xx,
434.x1, 436.xx) recorded in the primary diagnosis pos-
ition [10]. Both definitions were based on previously
published algorithms [9, 10]. PCI and CABG events were
based on an inpatient or outpatient medical claim with
an ICD-9-CM procedure, Current Procedure Termin-
ology, or Healthcare Common Procedure Coding System
codes for these procedures recorded in any position
(Additional file 1: Table S1). At the patient level, the
presence of each CV event and time from index date to
first evidence of each CV event were captured. The
number of each type of CV event experienced by a pa-
tient (i.e., the number of MIs that a single individual had
during follow-up) was not captured.
Covariates
Several demographic and clinical variables were captured.
The full list of covariates is presented in Tables 2 and 3.
Demographic characteristics were measured on the index
date and included age, sex, region (available only in com-
mercial data), and race (available only in Medicaid data).
Clinical characteristics were captured during the baseline
period. CV risk factors, such as CHADS2 score (a clas-
sification scheme used to predict stroke risk) [11, 12],
hypertension, dyslipidemia, and circulatory disease were
measured based on diagnoses on medical claims and pre-
scription claims. Additionally, characteristics of the initi-
ated ARV regimen were captured. Any ARV medication
filled on or within 13 days of the index date was consid-
ered part of the initiated regimen. A sensitivity analysis
was conducted on patients determined to be at high risk
for a CV event. Patients were considered high risk if they
met at least one of the following criteria: age 55–64, evi-
dence of diabetes, evidence of hypertension, evidence of
Table 1 Patient attrition for antiretroviral-naïve HIV+ patients initiating atazanavir-containing vs. atazanavir-free regimens
Criterion Commercial Database Medicaid Database
Patients with ≥1 prescription for an ARV medicationa between
1/1/2007 and 12/31/2013 (first claim = index date)
98,672 31,806
AND age 18–64 at index date 97,911 29,782
AND continuous enrollment for ≥6 months prior to index date 36,942 13,197
AND no eligibility for Medicare 36,942 13,181
AND no claims for ARV medications prior to index dateb 26,958 7,731
AND ≥1 claim with an HIV diagnosis prior to index dateb 22,285 7,185
AND no CV eventc in the 6 months prior to index date 22,211 7,136
Final Study Population 22,211 7,136
Initiated ATV-containing regimen 2,437 1,505
Initiated ATV-free regimen 19,774 5,631
Initiated PI-free regimen 16,131 3,931
Initiated other PI-containing regimen 3,643 1,700
Initiated DRV-containing regimen 1,551 527
ARV antiretroviral, ATV atazanavir, DRV darunavir, CV cardiovascular, PI protease inhibitor
aARV medications included non-nucleoside reverse transcriptase inhibitors, protease inhibitors (excluding ritonavir), integrase inhibitors, fusion inhibitors and CCR5
antagonists. bUsing all data prior to index date starting with 2004. cMyocardial infarction, stroke, percutaneous coronary intervention, or coronary artery bypass graft
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dyslipidemia, evidence of tobacco use disorder, or evi-
dence of circulatory disease.
Statistical analysis
The commercial and Medicaid patient populations were
analyzed separately in the descriptive analysis as the
rates of CV events in each population was of interest.
Patient characteristics were compared between the
ATV-containing and ATV-free cohorts using t-tests for
continuous variables and chi-squared tests for categor-
ical variables. Unadjusted incidence rates (IR) and 95 %
confidence intervals (CI) for each individual CV event
and the composite CV event were calculated as the
number of patients with the event divided by sum of
person-time during follow-up. Following the descriptive
analysis, the two patient populations were combined to
increase statistical power. Propensity score weights were
calculated using the covariates in Tables 2 and 3 to adjust
for baseline differences between the ATV-containing and
ATV-free cohorts. Two propensity scores were generated.
The first was a local propensity score which included all
variables available in each database and the second was a
universal propensity score which included all variables
that were available in both databases [13]. For example,
the local score for Medicaid included race while the
universal score did not, because race is not available in
the commercial data. To compare hazards of CV events,
propensity-score-weighted Cox proportional hazards models
were fit. Patients who did not experience a CV event were
considered censored at the end of follow-up. The same




There were 98,672 patients in the commercial database
and 31,806 in the Medicaid database who had at least
one claim for an ARV medication (Table 1). After apply-
ing the inclusion and exclusion criteria, the final sample
sizes were 22,211 and 7163 in the commercial and Me-
dicaid databases, respectively. Many potential patients
were excluded due to the pre-period continuous enroll-
ment criteria. However, this criterion was necessary for
appropriate assessment of baseline characteristics. In the
commercial sample, approximately 11 % of patients initi-
ated an ATV-containing regimen. There were significantly
fewer males in the ATV-containing regimen cohort than
the ATV-free cohort (Table 2). The proportions of pa-
tients with renal disease or hepatitis C were significantly
larger in the ATV-containing cohort (Table 3). CHADS2
scores were similar between the two cohorts. In the Me-
dicaid sample, approximately 21 % of patients initiated an
ATV-containing regimen. The proportion of patients with
white race was significantly lower in the ATV-containing
regimen cohort (Table 2). Compared with the patients ini-
tiating ATV-free regimens, a significantly larger propor-
tion of patients initiating ATV-containing regimens were
previously diagnosed with alcohol or drug abuse (Table 3).
Table 2 Demographic characteristics of antiretroviral-naïve HIV+ patients initiating atazanavir-containing vs. atazanavir-free regimens










N % N % N % N %
Age in Years (Mean, SD) 41.0 10.2 40.4 10.5 0.0055 41.2 10.9 41.3 11.2 0.6919
Male 1,863 76.4 % 16,566 83.8 % <.0001 746 49.6 % 2,883 51.2 % 0.2282
Regiona
Northeast 439 18.0 % 3,146 15.9 % 0.0002
North Central 290 11.9 % 2,896 14.6 %
South 1,229 50.4 % 10,174 51.5 %
West 440 18.1 % 3,300 16.7 %
Unknown 39 1.6 % 258 1.3 %
Raceb
White 206 13.7 % 964 17.1 % 0.0153
Black 1,088 72.3 % 3,894 69.2 %
Hispanic 16 1.1 % 76 1.3 %
Other 13 0.9 % 62 1.1 %
Unknown/Missing 182 12.1 % 635 11.3 %
Capitationc 548 22.5 % 3,754 19.0 % <.0001 609 40.5 % 2,256 40.1 % 0.7779
ATV atazanavir, SD standard deviation
aCommercial population only; bMedicaid population only; cPresence of claim with capitated payment arrangement
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Again, CHADS2 scores were similar between the two co-
horts. In both databases, more than half of patients initi-
ated a PI-free regimen. Of those patients, 74 % in both
databases initiated efavirenz. Results comparing the demo-
graphic and baseline clinical characteristics between pa-
tients initiating ATV-containing regimens and those
initiating PI-free regimens, other PI-containing regimens,
and DRV-containing regimens are presented in Additional
file 1: Tables S2 and S3.
For the primary analysis (as-treated), the mean follow-up
for ATV-containing cohorts was 12 months (median =
5 months) for the commercial sample and 9 months
(median = 4 months) for the Medicaid sample compared
to mean follow-up of 13 months (median = 7 months) and
9 months (median = 4 months), respectively, for the ATV-
free cohorts. For the ITT sensitivity analysis, the mean
follow-up for ATV-containing cohorts was 24 months
(median = 18 months) for the commercial sample and
23 months (median = 17 months) for the Medicaid sample
compared to mean follow-up of 21 months (median =
16 months) and 22 months (median = 15 months), re-
spectively, for the ATV-free cohorts.
CV events
CV events were rare in both databases. In the commer-
cial sample, incidence rates for each individual CV event
were less than 2 per 1000 person-years in both cohorts
(Fig. 1a and Additional file 1: Table S4A). For the com-
posite CV outcome, the incidence rates were similar for
the ATV-containing cohort (IR per 1000 person-years =
3.01, 95 % CI 1.21, 6.21) and the ATV-free cohort (IR
per 1000 person-years = 3.26, 95 % CI 2.53, 4.13). Pa-
tients initiating other PI-containing regimens tended to
have higher incidence of CV events (IR for composite
CV outcome per 1000 person-years = 6.63, 95 % CI 3.99,
10.36) (Additional file 1: Table S4A). Though still rare,
CV events were more common among Medicaid patients
than Commercial patients. IRs for the composite CV event
outcome in the Medicaid database were 10.94 per 1000
person-years (95 % CI 5.66, 19.12) for patients initiating
ATV-containing regimens and 9.92 per 1000 person-years
(95 % CI 7.06, 13.56) for patients initiating ATV-free regi-
mens (Fig. 1b and Additional file 1: Table S4B). IRs ranged
from 9.85 to 10.87 among the sub-cohorts of the ATV-free
regimens (Additional file 1: Table S4B).
Table 3 Baseline clinical characteristics of antiretroviral-naïve HIV+ patients initiating atazanavir-containing vs. atazanavir-free regimens










N % N % N % N %
CHADS2 Score
a
0 2,040 83.7 % 16,382 82.8 % 0.3593 1,019 67.7 % 3,745 66.5 % 0.6718
1 321 13.2 % 2,734 13.8 % 330 21.9 % 1,294 23.0 %
2 67 2.7 % 535 2.7 % 113 7.5 % 448 8.0 %
3–6 9 0.4 % 123 0.6 % 43 2.9 % 144 2.6 %
Diabetes Mellitusb 115 4.7 % 961 4.9 % 0.7597 137 9.1 % 563 10.0 % 0.2996
Hypertensionb 370 15.2 % 3,256 16.5 % 0.1058 450 29.9 % 1,733 30.8 % 0.5125
Dyslipidemiab 306 12.6 % 2,473 12.5 % 0.9438 158 10.5 % 576 10.2 % 0.7600
Renal Disease 107 4.4 % 640 3.2 % 0.0029 146 9.7 % 524 9.3 % 0.6404
Tobacco Use Disorder 110 4.5 % 986 5.0 % 0.3095 347 23.1 % 1,257 22.3 % 0.5448
COPD 37 1.5 % 279 1.4 % 0.6730 88 5.8 % 392 7.0 % 0.1253
Anemia 186 7.6 % 1,710 8.6 % 0.0905 283 18.8 % 1,088 19.3 % 0.6507
Hepatitis C 67 2.7 % 419 2.1 % 0.0448 173 11.5 % 595 10.6 % 0.3018
Alcohol Abuse Disorder 14 0.6 % 147 0.7 % 0.3536 90 6.0 % 246 4.4 % 0.0088
Drug Abuse Disorder 137 5.6 % 1,250 6.3 % 0.1780 488 32.4 % 1,666 29.6 % 0.0331
Autoimmune/Inflammatory
Disorders
86 3.5 % 731 3.7 % 0.6779 80 5.3 % 284 5.0 % 0.6700
Circulatory Disease 504 20.7 % 4,470 22.6 % 0.0316 570 37.9 % 2,178 38.7 % 0.5686
Oral Contraceptives 25 1.0 % 146 0.7 % 0.1255 13 0.9 % 42 0.7 % 0.6422
COPD chronic obstructive pulmonary disorder, ATV atazanavir, SD standard deviation
aCHADS2 is based on the presence of diagnoses of congestive heart failure, hypertension, diabetes, and stroke or transient ischemic attack and age ≥ 75 [11, 12];
bBoth diagnoses and medication use were evaluated
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After combining the commercial and Medicaid pa-
tients, hazard ratios weighted by the universal propensity
score for CV events comparing ATV-containing regi-
mens and ATV-free regimens were all not statistically
significant (Fig. 2 and Additional file 1: Table S5). The
hazard ratio for the composite CV outcome was 1.16
(95 % CI 0.67, 1.99). When limiting the sample to
patients at high risk for CV events, there was no signifi-
cant difference in the hazards of the composite CV out-
come between ATV-containing and ATV-free regimens
(hazard ratio = 1.16, 95 % CI 0.64-2.10). The hazard
ratios comparing ATV-containing regimens with PI-free,
other PI-containing, and DRV-containing regimens in
terms of the composite CV outcome were also non-
significant (Fig. 3 and Additional file 1: Table S5). The
findings were similar with the individual CV events
(Additional file 1: Table S5). Results weighted by the
local propensity score were similar and have not been
presented here. During the ITT follow-up period,
unadjusted IRs were higher than they were for the as-
treated follow-up periods but CV events were still rare
(Additional file 1: Tables S4A and S4B). All propensity-
score-weighted hazard ratios for comparisons were
nonsignificant (Additional file 1: Table S5).
Discussion
In this real-world analysis of HIV+ patients with com-
mercial or Medicaid insurance, CV events were rare,
though more common among Medicaid-insured pa-
tients. There was no significant increase in the risk of
CV events associated with exposure to ATV-containing
ARV regimens compared with ATV-free regimens. The
findings were the same when using an as-treated or ITT
follow-up. Additionally, there were no significant differ-
ences in risk of CV events between patients initiating
ATV-containing regimens compared to PI-free regimens,
other PI-containing regimens, or DRV-containing regi-
mens. These results lend additional evidence to the body
of literature reporting that exposure to ATV is not asso-
ciated with increased risk for CV events.
PIs are a commonly used class of medications to
treat HIV. The first medication within this class to be
approved was saquinavir in 1995 [14]. Currently, DRV/r
plus tenofovir/emtricitabine is listed as a recommended
Fig. 1 Incidence Rate per 1000 Person-Years for both a and b. Unadjusted incidence rates for cardiovascular events among commercially-insured
(a) and Medicaid-insured (b) HIV+ patients. ATV, atazanavir; CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; PCI,
percutaneous coronary intervention. Note. A single individual may have had more than one type of CV event and therefore, the sum of the
numbers of people with each individual event may be greater than the number of people with the composite CV event
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regimen and ATV/r plus tenofovir/emtricitabine is
listed as an alternative regimen for treatment-naïve
patients initiating ART [15]. However, PIs have been
associated with dyslipidemia, though the pathways by
which this occurs are not well understood [16]. In
turn, dyslipidemia is associated with poor cardiovas-
cular outcomes [17]. The same association with dys-
lipidemia may not exist for all medications within the
PI class.
PI use has also been linked to increased risk for CV
events in a number of analyses. A systematic review and
meta-analysis by Bavinger et al. identified articles and
abstracts published through 2011 [5]. They identified
three analyses which evaluated cumulative use of PIs
on the risk of MI [6, 18, 19]. The first, by Friis-Moller
and colleagues, analyzed PIs as a medication class and
found a significantly increased risk of MI with in-
creased cumulative PI exposure [6]. Bavinger combined
data from the two other analyses, by Worm et al. and
Lang et al. and found that both cumulative indinavir
use and cumulative lopinavir use was associated with
increased risk for MI [18, 19]. Bavinger and colleagues
also identified several studies which evaluated recent
use of PIs and CV events [20–25]. MI was the most
commonly evaluated CV outcome [21–25]. Three of
five analyses reported increased risk of MI with recent
PI exposure [22, 23, 25]. One conference abstract from
2010 by Triant and colleagues which analyzed specific
PIs reported an increase risk of MI following exposure
to nelfinavir or indinavir, specifically, but found no
association with ATV use [26].
Two more recently published analyses by Monforte
et al. and Stein et al. have also provided evidence against
a link between ATV exposure and increased CV risk
[7, 8]. Monforte and colleagues used D:A:D study data
to evaluate the association between cumulative expos-
ure to ATV and risk of MI or stroke [7]. MIs were rare
(incidence rate per 100 person-years for patients
Fig. 2 Propensity-score-weighted hazard ratios for CV events during as-treated follow-up period: Primary comparison. ATV, atazanavir; CABG, coronary
artery bypass graft; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention
Fig. 3 Propensity-score-weighted hazard ratios for composite CV event during as-treated follow-up period: Secondary comparisons. CI, confidence
interval; CV, cardiovascular; DRV, darunavir; HR, hazard ratio; PI, protease inhibitor
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unexposed to ATV = 0.28; for patients exposed to ATV
for more than 3 years = 0.20), as were strokes (inci-
dence rate per 100 person-years for patients unexposed
to ATV = 0.17; for patients exposed to ATV for more
than 3 years = 0.17) [7]. After controlling for demo-
graphics, clinical characteristics (including risk factors
such as body mass index and smoking status), and ex-
posure to other antiretroviral medications in Poisson
regression, there was no evidence of an association be-
tween cumulative exposure of ATV and MI (relative
rate/year = 0.95, 95 % CI 0.87-1.05) or stroke (relative
rate/year = 0.95, 95 % CI 0.87-1.05) [7]. In ACTG
5260s, Stein and colleagues evaluated carotid intima-
media thickness (IMT), which is a surrogate marker of
CV risk, in treatment-naïve patients randomized to
treatment with ATV/r plus tenofovir/emtricitabine,
DRV/r plus tenofovir/emtricitabine, or raltegravir (an inte-
grase inhibitor) plus tenofovir/emtricitabine [8]. Partici-
pants were followed for 144 weeks [8]. During follow-up,
non-high-density lipoprotein cholesterol and triglycerides
increased modestly in the ATV/r and DRV/r arms, and
carotid IMT measurements increased in all arms during
follow-up [8]. Carotid IMT progressed significantly more
slowly in participants treated with ATV/r compared with
patients treated with DRV/r [8]. The difference was even
greater in patients who remained on their regimen
throughout the follow-up period [8]. The comparison with
raltegravir also favored ATV/r but was only statistically
significant at the carotid bifurcation and in the on-
treatment analyses [8]. Carotid IMT is a well-validated
surrogate marker of atherosclerosis that has been shown
to be an independent predictor of stroke and myocardial
infarction [27–29].
Although the reason for the lack of association between
ATV and increased CV events is unclear, one potential
mechanism may be ATV-induced hyperbilirubinemia [30].
Bilirubin is known to have anti-atherosclerotic properties
[31], and multiple studies have shown that individuals
with Gilbert’s syndrome, a genetic deficiency in UGT1A1
resulting in a chronic low level hyperbilirubinemia, have a
reduced risk for CV events [32, 33]. In ACTG 5260s,
higher levels of on-treatment bilirubin were generally as-
sociated with slower progression of atherosclerosis [8].
This database analysis has several limitations and
strengths. The limitations include those common to
claims-based analyses. Claims are not collected for
research purposes. Therefore, miscoding may occur
that is non-differential by study cohorts, resulting in
misclassification of ATV use or CV events. Regarding
antiretroviral exposure, patients are assumed to take
their medications as directed. The validity of this as-
sumption is unknown. Regarding study outcomes, pre-
viously validated algorithms for MI and stroke [9, 10]
were used to reduce the possibility of misclassification.
Several patient characteristics related to CV risk, in-
cluding information about viral load, CD4 count, fam-
ily history, diet, exercise, smoking, and laboratory
values, were not available in these datasets. If these
factors were associated with both treatment and CV
events, the results may be biased due to uncontrolled
confounding. Additionally, patients may have been taking
other ARV or non-ARV medications that could affect CV
outcomes. Other than use of antihypertensive medications
and antihyperlipidemic medications in baseline, this ana-
lysis did not control for the use of other medications. Pro-
vider information, including prescribing preferences were
also not available in the claims data. As expected in a real-
world analysis, there were small but significant differences
between cohorts in some baseline characteristics such as
gender, race, and prevalence of renal disease. This re-
flects differing provider preferences when prescribing
ARV medications and was adjusted for using propensity-
score weighted models. Given the potential link between
abacavir exposure and increased CV risk [34], a Breslow-
Day test for effect measure modification was conducted to
determine if use of abacavir modified the relationship be-
tween ATV and CV events. The test was not significant.
However, the test may have been underpowered due to
the small number of events observed in this analysis, as ef-
fect modification has been noted in other claim-based
analyses [35]. The small number of events may have also
resulted in the study being underpowered to detect differ-
ences between the study cohorts, despite the large sample
sizes. Lastly, patients may not have been followed long
enough to develop these severe manifestations of CV dis-
ease, which may have resulted in the low prevalence of
CV events. A claims-based analysis with longer follow-up
would be helpful to confirm the lack of association be-
tween ATV use and CV events which was found here.
The strengths of this analysis include two large samples of
patients insured through a variety of plans. These patients
represent a geographically and socioeconomically diverse
group of HIV+ individuals. Additionally, this analysis is
US-based, whereas the majority of previous data on CV
events comes from D:A:D which is primarily based in Eur-
ope [36]. Lastly, this analysis includes more recent data
which allows for comparisons with more contemporary
ARVs.
Conclusions
The results of this analysis are consistent with prior
findings that there is no association between ATV ex-
posure and increased risk for CV events. While other re-
search indicates that the use of certain PIs increases risk
for these events, it does not appear to be a universal
class effect. This is an important consideration when
selecting the appropriate HIV regimen for patients at in-
creased risk of CV disease.
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